Nobuyuki Arima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nobuyuki Arima has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Mamiko Fujisue
Department of Breast Oncology, Kumamoto Shinto General Hospital, Kumamoto 862‑8655, Japan
4 shared publicationsYasuo Toyozumi
Department of Pathology, Kumamoto City Hospital, Kumamoto 862‑8505, Japan
4 shared publicationsYasuyuki Nishiyama
Department of Breast Surgery, Fukuoka Wajiro Hospital, Fukuoka 811‑0213, Japan
4 shared publicationsMasahiro Nakano
Department of Breast Oncology, Kumamoto Shinto General Hospital, Kumamoto 862‑8655, Japan
3 shared publicationsReiki Nishimura
Department of Breast Oncology, Kumamoto Shinto General Hospital, Kumamoto 862‑8655, Japan
3 shared publications- Reiki Nishimura
Department of Breast Surgery, Sagara Hospital Miyazaki, Miyazaki, Japan
3 shared publications
Latest Publications
- Open Access
Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which induce apoptosis by damaging target cells. To identify biomarkers of these cells, we investigated granzyme B (GZMB) in the tumor microenvironment as a biomarker of treatment response and prognosis in 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 and December 2014. Programmed cell death ligand 1 (PD-L1) positivity was defined as a composite positive score ≥10 based on the PD-L1 immunostaining of tumor cells and immune cells. GZMB-high was defined as positivity in ≥1% of tumor-infiltrating lymphocytes (TILs). Among the 230 TNBC patients, 117 (50.9%) had CD8-positive infiltrating tumors. In the PD-L1-positive group, a Kaplan–Meier analysis showed that GZMB-high TNBC patients had better recurrence-free survival (RFS) and overall survival (OS) than GZMB-low patients and that OS was significantly longer (RFS: p = 0.0220, OS: p = 0.0254). A multivariate analysis also showed significantly better OS in PD-L1- and GZMB-high patients (hazard ratio: 0.25 (95% IC: 0.07–0.88), p = 0.03). Our findings indicate that GZMB is a useful prognostic biomarker in PD-L1-positive TNBC patients.
Open AccessGranzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which induce apoptosis by damaging target cells. To identify biomarkers of these cells, we investigated granzyme B (GZMB) in the tumor microenvironment as a biomarker of treatment response and prognosis in 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 and December 2014. Programmed cell death ligand 1 (PD-L1) positivity was defined as a composite positive score ≥10 based on the PD-L1 immunostaining of tumor cells and immune cells. GZMB-high was defined as positivity in ≥1% of tumor-infiltrating lymphocytes (TILs). Among the 230 TNBC patients, 117 (50.9%) had CD8-positive infiltrating tumors. In the PD-L1-positive group, a Kaplan–Meier analysis showed that GZMB-high TNBC patients had better recurrence-free survival (RFS) and overall survival (OS) than GZMB-low patients and that OS was significantly longer (RFS: p = 0.0220, OS: p = 0.0254). A multivariate analysis also showed significantly better OS in PD-L1- and GZMB-high patients (hazard ratio: 0.25 (95% IC: 0.07–0.88), p = 0.03). Our findings indicate that GZMB is a useful prognostic biomarker in PD-L1-positive TNBC patients.
- Open Access
- 22 April 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2331
Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a heterogeneous genetic profile. The aim of this retrospective study was to evaluate the clinical significance of menopausal status in breast cancer cases with TNBC. Methods: Primary breast cancer patients who underwent curative surgery were enrolled in this retrospective study. A total of 5153 invasive breast cancer cases with Stage I–III were analyzed. The distribution of cases according to the menopausal status and subtypes was investigated and the clinicopathological characteristics and prognosis were compared between pre- and postmenopausal TNBC patients. Results: TNBC was frequently seen in postmenopausal patients and Luminal B and Luminal/HER2 subtypes were more common in premenopausal patients. There was no difference in DFS in the Luminal A/B and HER2 subtypes, but a significant difference was seen in the TNBC patients. Premenopausal patients with TNBC frequently had an overexpression of the p53 protein, a significantly higher Ki-67 index value, and a higher nuclear grade. A multivariate analysis revealed that menopausal status, nodal status, and tumor size were significant factors for DFS in TNBC cases. Conclusion: Menopausal status significantly correlates with breast cancer subtypes. TNBC was often seen in postmenopausal patients and these patients tend to have more favorable factors and a better DFS than premenopausal patients. These findings suggest that menopausal status is an important factor for evaluating biology and prognosis in TNBC cases.
- 22 April 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2331
Open AccessTriple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a heterogeneous genetic profile. The aim of this retrospective study was to evaluate the clinical significance of menopausal status in breast cancer cases with TNBC. Methods: Primary breast cancer patients who underwent curative surgery were enrolled in this retrospective study. A total of 5153 invasive breast cancer cases with Stage I–III were analyzed. The distribution of cases according to the menopausal status and subtypes was investigated and the clinicopathological characteristics and prognosis were compared between pre- and postmenopausal TNBC patients. Results: TNBC was frequently seen in postmenopausal patients and Luminal B and Luminal/HER2 subtypes were more common in premenopausal patients. There was no difference in DFS in the Luminal A/B and HER2 subtypes, but a significant difference was seen in the TNBC patients. Premenopausal patients with TNBC frequently had an overexpression of the p53 protein, a significantly higher Ki-67 index value, and a higher nuclear grade. A multivariate analysis revealed that menopausal status, nodal status, and tumor size were significant factors for DFS in TNBC cases. Conclusion: Menopausal status significantly correlates with breast cancer subtypes. TNBC was often seen in postmenopausal patients and these patients tend to have more favorable factors and a better DFS than premenopausal patients. These findings suggest that menopausal status is an important factor for evaluating biology and prognosis in TNBC cases.
- 29 October 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (1) , 616-622
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2‑enriched and basal‑like, and immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER‑positive, HER2‑negative and negative nodes were classified into 4 groups according to the PgR and the Ki‑67 status and were retrospectively examined. The analysis was based on the clinicopathological findings, and includes the recurrence score (RS) and disease‑free survival (DFS) rates. Patients with invasive breast cancer (n=1866) were classified as LA (high PgR/low Ki‑67), LB‑1 (high PgR/high Ki‑67), LB‑2 (low PgR/high Ki‑67), and LB‑3 (low PgR/low Ki‑67). In addition, 41 of the cases underwent a 21‑gene expression assay. The data revealed that T1 tumors were more prevalent in the LA group and rare in the LB‑2 group. Furthermore, nuclear grade 3 and p53 overexpression was revealed to be significantly correlated with LB‑2. In terms of prognosis, LA had a significantly more favorable DFS; however, no differences were observed in the LB‑3 group. LB‑2 had a significantly worse DFS in all cases, and in the cases administered with endocrine therapy alone. Chemotherapy in combination with endocrine therapy was administered to cases with a higher risk of recurrence. In the LB‑2 group, there was no difference in the DFS rates between the cases with endocrine therapy and chemo‑endocrine therapy. These findings suggest that chemotherapy could improve the DFS in the LB‑2 group. In addition, the majority of cases with LA, LB‑3 and LB‑1 had a RS of ≤25 and the majority of the LB‑2 cases had a RS of >25. The patients with LA and LB‑3 had a favorable DFS even in the group that received endocrine therapy alone. LB‑2 was significantly correlated with a higher degree of malignancy and benefited from chemotherapy. These data suggest that the PgR and the Ki‑67 status are effective in predicting prognosis, and for deciding on the most effective treatment strategy in patients with breast cancer.
- 29 October 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (1) , 616-622
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2‑enriched and basal‑like, and immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER‑positive, HER2‑negative and negative nodes were classified into 4 groups according to the PgR and the Ki‑67 status and were retrospectively examined. The analysis was based on the clinicopathological findings, and includes the recurrence score (RS) and disease‑free survival (DFS) rates. Patients with invasive breast cancer (n=1866) were classified as LA (high PgR/low Ki‑67), LB‑1 (high PgR/high Ki‑67), LB‑2 (low PgR/high Ki‑67), and LB‑3 (low PgR/low Ki‑67). In addition, 41 of the cases underwent a 21‑gene expression assay. The data revealed that T1 tumors were more prevalent in the LA group and rare in the LB‑2 group. Furthermore, nuclear grade 3 and p53 overexpression was revealed to be significantly correlated with LB‑2. In terms of prognosis, LA had a significantly more favorable DFS; however, no differences were observed in the LB‑3 group. LB‑2 had a significantly worse DFS in all cases, and in the cases administered with endocrine therapy alone. Chemotherapy in combination with endocrine therapy was administered to cases with a higher risk of recurrence. In the LB‑2 group, there was no difference in the DFS rates between the cases with endocrine therapy and chemo‑endocrine therapy. These findings suggest that chemotherapy could improve the DFS in the LB‑2 group. In addition, the majority of cases with LA, LB‑3 and LB‑1 had a RS of ≤25 and the majority of the LB‑2 cases had a RS of >25. The patients with LA and LB‑3 had a favorable DFS even in the group that received endocrine therapy alone. LB‑2 was significantly correlated with a higher degree of malignancy and benefited from chemotherapy. These data suggest that the PgR and the Ki‑67 status are effective in predicting prognosis, and for deciding on the most effective treatment strategy in patients with breast cancer.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e12020
Biology and prognosis of HER2-negative breast cancer with low-ER and PgR-expressions.
E12020 Background: Expression of the estrogen (ER) and progesterone receptor (PgR) is still clinically important in predicting prognosis and determining therapeutic strategies in breast cancer. According to the ASCO and CAP guidelines tumors with ≥1% positively staining cells should be considered ER/PgR positive. The clinical significance of low-ER/PgR-staining (1-9%) tumors were analyzed to investigate the biology and prognosis. Methods: This study examined 3193 consecutive HER2 negative invasive breast cancer cases. Clinicopathological characteristics and prognosis of hormone receptor (HR)-negative (<1%), low-HR-staining (1-9%) tumors and positive (≥ 10%) tumors were compared. The median follow-up period was 75 months. Results: The following is the number of patients in each of the tumor categories: 466 ER cases (14.6%) and 775 PgR cases (24.2%) in the <1% group; 68 ER cases (2.1%) and 218 PgR cases (6.8%) in the 1-9% group; and 2559 ER cases and 2200 PgR cases in the ≥ 10% group. The age groups were; young (≤35 y), premenopausal (36-50 y), postmenopausal (51-65 y) and the elderly (≥66 y). The median ER positive cell rate was significantly lower in the young group. In contrast, the PgR expression was significantly higher in the premenopausal group and significantly lower in the postmenopausal group. Patients in the ≥10% group had significantly smaller tumors, lower Ki-67 values, a lower p53 overexpression and nuclear grade. The elderly group had better disease-free survival (DFS) and the young group had the lowest DFS. In addition, DFS by ER/PgR expression was more favorable in the ≥ 10% group than the other groups. Patients with 1-9% ER had significantly lower DFS than those in the ≥10% elderly group. Patients with 1-9% PgR had significantly lower DFS than those in all the ≥10% groups and significantly lower DFS than those in the <1% premenopausal group. Multivariate analysis for DFS revealed that PgR expression, lymph node metastasis and tumor size were significant prognostic factors. Conclusions: There was a clear difference in the PgR expression rate due to the menopausal status. Moreover, the 1-9% ER and PgR groups had biological features that were similar to ER/PgR-negative tumors.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e12020
Biology and prognosis of HER2-negative breast cancer with low-ER and PgR-expressions.
E12020 Background: Expression of the estrogen (ER) and progesterone receptor (PgR) is still clinically important in predicting prognosis and determining therapeutic strategies in breast cancer. According to the ASCO and CAP guidelines tumors with ≥1% positively staining cells should be considered ER/PgR positive. The clinical significance of low-ER/PgR-staining (1-9%) tumors were analyzed to investigate the biology and prognosis. Methods: This study examined 3193 consecutive HER2 negative invasive breast cancer cases. Clinicopathological characteristics and prognosis of hormone receptor (HR)-negative (<1%), low-HR-staining (1-9%) tumors and positive (≥ 10%) tumors were compared. The median follow-up period was 75 months. Results: The following is the number of patients in each of the tumor categories: 466 ER cases (14.6%) and 775 PgR cases (24.2%) in the <1% group; 68 ER cases (2.1%) and 218 PgR cases (6.8%) in the 1-9% group; and 2559 ER cases and 2200 PgR cases in the ≥ 10% group. The age groups were; young (≤35 y), premenopausal (36-50 y), postmenopausal (51-65 y) and the elderly (≥66 y). The median ER positive cell rate was significantly lower in the young group. In contrast, the PgR expression was significantly higher in the premenopausal group and significantly lower in the postmenopausal group. Patients in the ≥10% group had significantly smaller tumors, lower Ki-67 values, a lower p53 overexpression and nuclear grade. The elderly group had better disease-free survival (DFS) and the young group had the lowest DFS. In addition, DFS by ER/PgR expression was more favorable in the ≥ 10% group than the other groups. Patients with 1-9% ER had significantly lower DFS than those in the ≥10% elderly group. Patients with 1-9% PgR had significantly lower DFS than those in all the ≥10% groups and significantly lower DFS than those in the <1% premenopausal group. Multivariate analysis for DFS revealed that PgR expression, lymph node metastasis and tumor size were significant prognostic factors. Conclusions: There was a clear difference in the PgR expression rate due to the menopausal status. Moreover, the 1-9% ER and PgR groups had biological features that were similar to ER/PgR-negative tumors.
- 28 November 2015
- Published by S. Karger AG in Oncology
- Vol. 90 (1) , 43-50
A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer
Objective: In this case-control study, we investigated the most suitable cell counting area and the optimal cutoff point of the Ki-67 index. Methods: Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cancer patients. As controls, 90 nonrecurrent cases were randomly selected by allotting 3 controls to each recurrent case based on the following criteria: age, nodal status, tumor size, and adjuvant endocrine therapy alone. Both the hot spot and the average area of the tumor were evaluated on a Ki-67 immunostaining slide. Results: The median Ki-67 index value at the hot spot and average area were 25.0 and 14.5%, respectively. Irrespective of the area counted, the Ki-67 index value was significantly higher in all of the recurrent cases (p < 0.0001). The multivariate analysis revealed that the Ki-67 index value of 20% at the hot spot was the most suitable cutoff point for predicting recurrence. Moreover, higher ΔKi-67 index value (the difference between the hot spot and the average area, ≥10%) and lower progesterone receptor expression (<20%) were significantly correlated with recurrence. Conclusion: A higher Ki-67 index value at the hot spot strongly correlated with recurrence, and the optimal cutoff point was found to be 20%.
- 28 November 2015
- Published by S. Karger AG in Oncology
- Vol. 90 (1) , 43-50
A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer
Objective: In this case-control study, we investigated the most suitable cell counting area and the optimal cutoff point of the Ki-67 index. Methods: Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cancer patients. As controls, 90 nonrecurrent cases were randomly selected by allotting 3 controls to each recurrent case based on the following criteria: age, nodal status, tumor size, and adjuvant endocrine therapy alone. Both the hot spot and the average area of the tumor were evaluated on a Ki-67 immunostaining slide. Results: The median Ki-67 index value at the hot spot and average area were 25.0 and 14.5%, respectively. Irrespective of the area counted, the Ki-67 index value was significantly higher in all of the recurrent cases (p < 0.0001). The multivariate analysis revealed that the Ki-67 index value of 20% at the hot spot was the most suitable cutoff point for predicting recurrence. Moreover, higher ΔKi-67 index value (the difference between the hot spot and the average area, ≥10%) and lower progesterone receptor expression (<20%) were significantly correlated with recurrence. Conclusion: A higher Ki-67 index value at the hot spot strongly correlated with recurrence, and the optimal cutoff point was found to be 20%.
- Open Access
- 29 September 2015
- Published by BMJ in Journal of Clinical Pathology
- Vol. 69 (3) , 255-259
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index
Aim Insufficient attention for the Ki-67 immunohistochemistry has been given to the importance of tissue handling for surgical breast cancer specimens. We sought to investigate the effect of fixation status on the Ki-67. Methods We examined the effect of fixative, time to and duration of fixation using surgical specimens, and finally, compared the paired Ki-67 index in the tumour between core needle and surgical specimen. Results The Ki-67 was significantly higher when 10% neutral buffered formalin was used (p=0.0276). Insufficient fixation caused a drastic reduction in the Ki-67 index (p=0.0177), but not significant in oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). Sixteen hours delayed time to fixation also caused a reduction of the Ki-67 (p=0.0284), but not significant in ER. Prolonged fixation significantly led to a gradual reduction in the Ki-67 in a time-dependent manner, but not in both ER and HER2. Finally, cutting the tumour before fixation improved fixation status and consequently caused an increased level of the Ki-67 index (p=0.0181), which resulted in a strong correlation of the Ki-67 between core needle and surgical specimen (r=0.8595). Conclusions Tissue handling of surgical specimen is critical for assessing the Ki-67 compared with ER and HER2. We should pay more attention to tissue fixation status for the standard assessment of the Ki-67 index.
- 29 September 2015
- Published by BMJ in Journal of Clinical Pathology
- Vol. 69 (3) , 255-259
Open AccessThe importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index
Aim Insufficient attention for the Ki-67 immunohistochemistry has been given to the importance of tissue handling for surgical breast cancer specimens. We sought to investigate the effect of fixation status on the Ki-67. Methods We examined the effect of fixative, time to and duration of fixation using surgical specimens, and finally, compared the paired Ki-67 index in the tumour between core needle and surgical specimen. Results The Ki-67 was significantly higher when 10% neutral buffered formalin was used (p=0.0276). Insufficient fixation caused a drastic reduction in the Ki-67 index (p=0.0177), but not significant in oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). Sixteen hours delayed time to fixation also caused a reduction of the Ki-67 (p=0.0284), but not significant in ER. Prolonged fixation significantly led to a gradual reduction in the Ki-67 in a time-dependent manner, but not in both ER and HER2. Finally, cutting the tumour before fixation improved fixation status and consequently caused an increased level of the Ki-67 index (p=0.0181), which resulted in a strong correlation of the Ki-67 between core needle and surgical specimen (r=0.8595). Conclusions Tissue handling of surgical specimen is critical for assessing the Ki-67 compared with ER and HER2. We should pay more attention to tissue fixation status for the standard assessment of the Ki-67 index.
- 6 January 2013
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (6) , 1886-1892
Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence
There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR).
- 6 January 2013
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (6) , 1886-1892
Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence
There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR).
- 1 June 2000
- Published by Wiley in Pathology International
- Vol. 50 (6) , 520-525
Ovarian yolk sac tumor with virilization during pregnancy: Immunohistochemical demonstration of Leydig cells as functioning stroma
A case is reported of yolk sac tumor occurring in the left ovary and complicated by pregnancy. The 22‐year‐old patient presented at 28 weeks gestation with virilization and elevated serum levels of testosterone and alpha‐fetoprotein. The tumor showed the typical features of yolk sac tumor with a mixture of islands of Leydig cells. The accumulations of Leydig cells were well demarcated from the cellular components of the yolk sac tumor and were distributed throughout the tumor, although with predominant localization at the periphery. By immunohistochemistry the Leydig cells were intensely positive for vimentin and negative for cytokeratins, allowing clear distinction from the cell components of the yolk sac tumor, which were positive for cytokeratins and negative for vimentin. Testosterone was also identified in the cytoplasm of the Leydig cells. After tumor resection the testosterone and alpha‐fetoprotein levels declined simultaneously; this, together with the immunohistochemical demonstration of testosterone, indicates that the Leydig cells were responsible for the endocrine manifestations. Furthermore, antibodies against inhibin alpha‐subunit and calretinin could be used to detect the Leydig cells. The present case, a combination of yolk sac tumor and Leydig cells acting as a functioning stroma and causing virilization during pregnancy, is very rare.
- 1 June 2000
- Published by Wiley in Pathology International
- Vol. 50 (6) , 520-525
Ovarian yolk sac tumor with virilization during pregnancy: Immunohistochemical demonstration of Leydig cells as functioning stroma
A case is reported of yolk sac tumor occurring in the left ovary and complicated by pregnancy. The 22‐year‐old patient presented at 28 weeks gestation with virilization and elevated serum levels of testosterone and alpha‐fetoprotein. The tumor showed the typical features of yolk sac tumor with a mixture of islands of Leydig cells. The accumulations of Leydig cells were well demarcated from the cellular components of the yolk sac tumor and were distributed throughout the tumor, although with predominant localization at the periphery. By immunohistochemistry the Leydig cells were intensely positive for vimentin and negative for cytokeratins, allowing clear distinction from the cell components of the yolk sac tumor, which were positive for cytokeratins and negative for vimentin. Testosterone was also identified in the cytoplasm of the Leydig cells. After tumor resection the testosterone and alpha‐fetoprotein levels declined simultaneously; this, together with the immunohistochemical demonstration of testosterone, indicates that the Leydig cells were responsible for the endocrine manifestations. Furthermore, antibodies against inhibin alpha‐subunit and calretinin could be used to detect the Leydig cells. The present case, a combination of yolk sac tumor and Leydig cells acting as a functioning stroma and causing virilization during pregnancy, is very rare.